The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Apr. 23, 2024
Filed:
May. 28, 2019
Applicant:
Hua Medicine (Shanghai) Ltd., Shanghai, CN;
Inventors:
Li Chen, Shanghai, CN;
Yongguo Li, Shanghai, CN;
Gaosen Wang, Shanghai, CN;
Huisheng Gao, Shanghai, CN;
Assignee:
HUA Medicine (Shanghai) Ltd., Shanghai, CN;
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/4155 (2006.01); A61K 9/16 (2006.01); A61K 9/20 (2006.01); A61K 9/28 (2006.01); A61K 31/155 (2006.01); A61K 31/40 (2006.01); A61K 31/403 (2006.01); A61K 31/4035 (2006.01); A61K 31/4439 (2006.01); A61K 31/4985 (2006.01); A61K 31/522 (2006.01); A61K 31/7034 (2006.01); A61K 45/06 (2006.01); A61K 47/38 (2006.01); A61P 3/10 (2006.01); C07D 231/38 (2006.01); C07D 403/12 (2006.01);
U.S. Cl.
CPC ...
A61K 31/4155 (2013.01); A61K 9/1611 (2013.01); A61K 9/1617 (2013.01); A61K 9/1635 (2013.01); A61K 9/1694 (2013.01); A61K 9/2009 (2013.01); A61K 9/2013 (2013.01); A61K 9/2027 (2013.01); A61K 9/2054 (2013.01); A61K 9/2086 (2013.01); A61K 9/2095 (2013.01); A61K 9/2813 (2013.01); A61K 9/284 (2013.01); A61K 9/2866 (2013.01); A61K 31/155 (2013.01); A61K 31/40 (2013.01); A61K 31/403 (2013.01); A61K 31/4035 (2013.01); A61K 31/4439 (2013.01); A61K 31/4985 (2013.01); A61K 31/522 (2013.01); A61K 31/7034 (2013.01); A61K 45/06 (2013.01); A61K 47/38 (2013.01); A61P 3/10 (2018.01); C07D 231/38 (2013.01); C07D 403/12 (2013.01);
Abstract
Disclosed is a pharmaceutical combination comprising a glucokinase activator or a pharmaceutically acceptable salt thereof, an isotopic label thereof, a crystalline form thereof, a hydrate, a solvate, a diastereomeric or enantiomeric form thereof, and a DPP-IV inhibitor. Disclosed are a pharmaceutical composition and a fixed dose of a compound preparation, and the methods for preparing the pharmaceutical composition and the fixed dose of the compound preparation and the uses thereof.